CN109862907A - 抗Kv1.3抗体及其生产方法和用途 - Google Patents

抗Kv1.3抗体及其生产方法和用途 Download PDF

Info

Publication number
CN109862907A
CN109862907A CN201780041381.XA CN201780041381A CN109862907A CN 109862907 A CN109862907 A CN 109862907A CN 201780041381 A CN201780041381 A CN 201780041381A CN 109862907 A CN109862907 A CN 109862907A
Authority
CN
China
Prior art keywords
antibody
limited
cell
present
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780041381.XA
Other languages
English (en)
Chinese (zh)
Inventor
L.马里恩
B.范德沃宁格
H.德哈德
W.D.哈里曼
E.J.科拉里尼
P.科卢西
J.比德宁科
Y.比沙彦
A.帕波彦
J.卡达尔里
T.G.克拉克
R.D.卡恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tetra Gene Co Ltd
Original Assignee
Tetra Gene Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tetra Gene Co Ltd filed Critical Tetra Gene Co Ltd
Publication of CN109862907A publication Critical patent/CN109862907A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201780041381.XA 2016-05-02 2017-05-02 抗Kv1.3抗体及其生产方法和用途 Pending CN109862907A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662330420P 2016-05-02 2016-05-02
US62/330,420 2016-05-02
US201662416447P 2016-11-02 2016-11-02
US62/416,447 2016-11-02
PCT/US2017/030612 WO2017192567A1 (en) 2016-05-02 2017-05-02 ANTI-Kv1.3 ANTIBODIES, AND METHODS OF PRODUCTION AND USE THEREOF

Publications (1)

Publication Number Publication Date
CN109862907A true CN109862907A (zh) 2019-06-07

Family

ID=60203481

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780041381.XA Pending CN109862907A (zh) 2016-05-02 2017-05-02 抗Kv1.3抗体及其生产方法和用途

Country Status (8)

Country Link
US (1) US11597763B2 (https=)
EP (1) EP3452084A4 (https=)
JP (2) JP7082065B2 (https=)
CN (1) CN109862907A (https=)
AU (1) AU2017260232B2 (https=)
CA (1) CA3022961A1 (https=)
IL (1) IL262747A (https=)
WO (1) WO2017192567A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120865419A (zh) * 2025-08-02 2025-10-31 广东工业大学 一种用于检测肝癌标志物gpc3的禽源单链抗体、试剂盒、检测方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113559075A (zh) 2014-11-17 2021-10-29 康泰科思特生物制药公司 奥那司酮延长释放组合物和方法
WO2018102369A1 (en) 2016-11-30 2018-06-07 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection
EP3793614A4 (en) 2018-04-30 2022-04-20 Integral Molecular, Inc. GLUCOSE TRANSPORTER-4 ANTIBODIES, PROCESSES FOR THEIR PRODUCTION AND THEIR USES
EP3924389A4 (en) 2019-02-15 2023-06-14 Integral Molecular, Inc. CLAUDIN-6 ANTIBODIES AND THEIR USES
CN113661175A (zh) 2019-02-15 2021-11-16 整体分子公司 包含共同轻链的抗体及其用途
CA3176090A1 (en) * 2020-03-30 2021-10-07 Crystal Bioscience Inc. Anti-gipr antibody and methods of use thereof
EP4626933A1 (en) 2022-11-30 2025-10-08 Integral Molecular, Inc. Antibodies directed to claudin 6, including bispecific formats thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102180950A (zh) * 2011-02-24 2011-09-14 华中科技大学同济医学院附属协和医院 一种人源性电压门控钾通道1.3免疫原性肽段及其用途
CN104937105A (zh) * 2013-01-25 2015-09-23 詹森生物科技公司 Kv1.3拮抗剂及其使用方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861405B2 (en) * 2001-06-12 2005-03-01 Yale University Compositions and methods relating to glucose metabolism, weight control, and food intake
US7319142B1 (en) * 2004-08-31 2008-01-15 Monsanto Technology Llc Nucleotide and amino acid sequences from Xenorhabdus and uses thereof
AU2006324847A1 (en) 2005-12-15 2007-06-21 Genegrafts Ltd. Polynucleotides and polypeptide of Human KV1.3, compositions comprising same and methods of using same
WO2007139771A1 (en) 2006-05-22 2007-12-06 The Johns Hopkins University Kv channels in neurodegeneration and neuroprotection
WO2010126590A1 (en) 2009-04-27 2010-11-04 Cold Spring Harbor Laboratory Ptp1b inhibitors
EP2287202A1 (en) 2009-08-07 2011-02-23 Dublin City University Anti-sialic acid antibody molecules
JP5765814B6 (ja) 2009-10-21 2018-06-27 国立大学法人広島大学 インテグリンα８β１特異的モノクローナル抗体
WO2014016737A1 (en) 2012-07-24 2014-01-30 Pfizer Inc. Novel chicken monoclonal antibodies against human phosphorylated tau and uses thereof
CN103713129B (zh) 2013-12-18 2016-02-10 中国医学科学院北京协和医院 分子标记物在甲状旁腺肿瘤诊断中的用途
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102180950A (zh) * 2011-02-24 2011-09-14 华中科技大学同济医学院附属协和医院 一种人源性电压门控钾通道1.3免疫原性肽段及其用途
CN104937105A (zh) * 2013-01-25 2015-09-23 詹森生物科技公司 Kv1.3拮抗剂及其使用方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MIREIA PÉREZ-VERDAGUER等: "The voltage-gated potassium channel Kv1.3 is a promising multitherapeutic target against human pathologies", 《EXPERT OPINION ON THERAPEUTIC TARGETS》 *
丁莉等: "自身免疫病新靶标Kv1.3及其药用多肽研究进展", 《湖北医学院学报》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120865419A (zh) * 2025-08-02 2025-10-31 广东工业大学 一种用于检测肝癌标志物gpc3的禽源单链抗体、试剂盒、检测方法

Also Published As

Publication number Publication date
WO2017192567A1 (en) 2017-11-09
JP7082065B2 (ja) 2022-06-07
EP3452084A1 (en) 2019-03-13
IL262747A (en) 2018-12-31
EP3452084A4 (en) 2020-01-01
AU2017260232A1 (en) 2018-11-29
US11597763B2 (en) 2023-03-07
AU2017260232B2 (en) 2024-07-18
CA3022961A1 (en) 2017-11-09
JP2019521651A (ja) 2019-08-08
JP2022002541A (ja) 2022-01-11
US20190144538A1 (en) 2019-05-16

Similar Documents

Publication Publication Date Title
CN109862907A (zh) 抗Kv1.3抗体及其生产方法和用途
TWI848090B (zh) 密蛋白抗體及其應用
CN110366560B (zh) 抗b7-h4抗体、其抗原结合片段及其医药用途
AU2019254934B2 (en) Monoclonal antibody of nerve growth factor and encoding gene and use thereof
JP2014005301A (ja) 中和抗体およびその使用方法
KR20050049470A (ko) 항 수초 관련 당단백질 항체
JP7533897B2 (ja) 融合タンパク質およびその使用
US9567404B2 (en) Anti-vasa antibodies, and methods of production and use thereof
KR20150013935A (ko) 트랜스포터에 대한 항체 및 이의 용도
WO2011140151A1 (en) Antibodies against epidermal growth factor receptor (egfr)
CN104045713B (zh) 一种抗Blys的单克隆抗体及含有该抗体的药物组合物
Coomber et al. Generation of anti-p53 Fab fragments from individuals with colorectal cancer using phage display
US20240390418A1 (en) Anti-variable muc1* antibodies and uses thereof
WO2024012434A1 (en) Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
CN104861068A (zh) 一种全人源抗her3抗体及含有该抗体的组合物和其用于制备治疗her3相关疾病的药物中的用途
WO2021034952A1 (en) Anti-cd19 antibodies and uses thereof
HK40045914A (en) Monoclonal antibody of nerve growth factor and encoding gene and use thereof
CN102311499A (zh) 一种癌症治疗用人源化单克隆抗体及其制备及应用
Strube Anti-HER2/Toxin Expressing Lymphocytes for Breast Cancer Therapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination